The prevalence of depression, anxiety, and stress in patients with breast cancer in Southeast Iran in 2019: a cross-sectional study

ABSTRACT
Introduction. Today, breast cancer patients suffer from various psychological symptoms that impose irreversible effects on their quality of life. The aim of the present study was to determine the prevalence of depression, anxiety, and stress in patients with breast cancer.

Material and methods. This descriptive study was performed on 190 women with breast cancer from January 1, 2019 to July 30, 2019. Data collection was carried out using a convenience sampling method. The Standard Depression, Anxiety, and Stress Scale (DASS-21) was used to assess depression, anxiety, and stress.

Results. The mean age of the patients was 46.3 years. Results showed the prevalence of depression, anxiety, and stress to be 28.4%, 43.2%, and 14.7%, respectively.

Conclusion. The results indicate that it is vital to measure the level of depression and anxiety in women with breast cancer, which are two common mental disorders in breast cancer.

Key words: breast cancer, depression, anxiety, stress
patients is anxiety, the prevalence of anxiety is 41.9% [13]. Anxiety is associated with cancer, and these psychological symptoms are the most common psychological symptoms found in cancer patients. Patients with ineffective coping strategies exhibit higher levels of anxiety and depression, and social support led to a significant decrease in the level of anxiety and depression [14, 15]. Stress or perceived stress was also expressed as another psychological factor in cancer patients and was strongly related with depression [16]. Determining the exact level of depression and anxiety can help policymakers and healthcare providers plan for better control of these diseases. The aim of the present study was to determine the prevalence of depression, anxiety, and stress among patients with breast cancer.

**Methods**

**Design**

This cross-sectional study was performed on 190 women with breast cancer stages 3–4 referred to oncology wards of three educational hospitals in three Iranian cities (Zahedan, Arak, and Mashhad) from 1 January 2019 to 30 July 2019. Patients were selected through convenience sampling. Inclusion criteria included patients aged above 18 years, with no systemic disease.

**Instruments**

The standard depression, anxiety, and stress scale — 21 items (DASS-21) was used to assess depression, anxiety, and stress in patients [17]. This instrument consisted of 21 items, with seven items for each subscale. The instrument was scored based on a four-point Likert scale ranging from 0 to 3 (never, rarely, sometimes, and always). Depression levels were categorised into four categories, which indicated normal (score: 0–9), low (score: 10–13), moderate (score: 14–20), and severe (28 and above) level of depression. Normal, low, moderate, severe, and very severe anxiety were also indicated by scores of 0–7, 8–9, 10–14, 15–19, and 20 and above, respectively. The validity and reliability of this instrument has been confirmed in various Iranian [18, 19] and international (non-Iranian) [20, 21] populations. The demographic characteristics studied included age, city of residence, level of education, and marital status.

**Data collection**

Data collection was carried out after making coordination with the hospital cancer department and explaining the study objectives to the patients in simple language. Questionnaires were then distributed among the qualified patients who expressed their consent to participate in the study. Patients were given 15 minutes to complete the questionnaires. Questionnaires were completed by the researcher in the case of illiterate participants.

**Ethical considerations**

The present study was approved by the Ethics Committee of Zahedan University of Medical Sciences (Ethic code: IR.ZAUMS.REC.1392.5962). Written and oral consent was obtained from all participants, and they were assured that their information would be kept confidential. The STROBE checklist was also used to report the study [22].

**Statistical analysis**

Descriptive statistical tests (mean, standard deviation, frequency, and percentage) were used to describe demographic characteristics of the participants and analytical tests (chi-square) were also used to examine the relationship between demographic characteristics with stress, anxiety, and depression. SPSS Version 18.0 for Windows (SPSS Inc., Chicago, IL, USA) was used to analyse the data. Confidence interval of 95% and a significance level of P < 0.05 was considered significant.

**Results**

All 190 patients with breast cancer were evaluated (response rate = 100%). The mean age of patients was 46.3 years (range: 19–76 years). The majority of the participants lived in Zahedan (77.9%), had high school education (25.3%), and were married (84.2%) (Table 1).

The prevalence of mild, moderate, and severe depression was 18.4%, 9.5%, and 0.5%, respectively. The prevalence of anxiety was 43.2%. The average prevalence of stress was 14.7%, with 12.6%, 1.6%, and 0.5%, for mild, moderate, and severe stress, respectively (Table 2).

**Discussion**

The present study investigated the prevalence of psychological factors (depression, anxiety, and stress) in breast cancer patients and revealed that 28.4%, 43.2%, and 14.7% of patients suffered from depression, anxiety, and stress, respectively. Approximately one-third (28.4%) of patients suffered from depression, which is similar to the global prevalence of depression (32.2%) and to results from studies car-
ried out by Montazeri et al. (29.4%) [23], Taghavi et al. (34.2%) [24], and Nikbakhsh et al. (27.5%) [25] in different parts of Iran. The above figure was, however, lower than the rate reported in studies by Ramezani et al. [26] and Mashhadi et al. [27]. This difference could be due to differences in participants’ place of residence, demographic characteristics of participants, methodological differences of the studies, and sample size.

High levels of mental distress for sustained periods of time in cancer patients may lead to anxiety, depression, or both [28]. The mortality rate is higher in depressed cancer patients than non-depressed patients [6]. Depression is very common in breast cancer patients; the prevalence of depression is 47.4% [10, 29], which can significantly affect the quality of life of patients [30]. According to various studies, the prevalence of depression in cancer patients ranges from 16–67% [31–33].

The prevalence of anxiety in the present study was 43.2%, which was close to the global prevalence of anxiety (41.9%) [13] and lower than the figure reported in the study by Ashbury (77%) [13]. Anxiety had a significant effect on the feeling of breast cancer patients and their coping mechanisms [34]. Results of a study showed that 16% of women with breast cancer were diagnosed as depressed until 6 to 13 years after treatment [35]. Other studies have shown that the prevalence of depression in cancer patients is estimated to be 15–30% or higher [(36–38], and although anxiety and depression are commonly seen in breast cancer patients, exacerbate the symptoms of the disease, and lead to no response to treatment, these mental disorders are ignored and left untreated [39]. Achieving understanding of these common mental disorders and related psychosocial factors can help plan treatment and may lead to more successful treatment [40]. Lueboonthavatchai concluded that the prevalence of anxiety disorder and anxiety symptoms was 16% and 19%, respectively [41]. Theoretically, stress is defined as the body’s response to environmental or mental conflicts, or as the internal response that depends on their ability to cope with environmental stress [42]. In a meta-analysis, researchers concluded that stressful events are not associated with the risk of breast cancer in women [43]; however, high-intensity stress may be a potential risk factor for breast cancer. A study by Nikbakhsh et al. on 150 cancer patients in Iran showed that 44 participants (29.3%) had mild anxiety and 25 (16.7%) had symptomatic anxiety and mild depression, which is inconsistent with the present study, which showed lower stress rates [25]. This difference could be due to the type of cancer being studied and methodological differences.

Table 1. Participants demographic characteristics of breast cancer patients (n = 190)

| Variables                        | N (%) | Mean ± SD |
|----------------------------------|-------|-----------|
| Age (years)                      | 46.3 ± 12.2 |
| City of residence                |       |           |
| Zahedan                          | 148 (77.9) |
| Mashhad                          | 23 (12.1)  |
| Arak                             | 19 (10)   |
| Education level                  |       |           |
| Illiterate                       | 39 (20.5)  |
| Elementary                       | 45 (23.7)  |
| Secondary                        | 23 (12.1)  |
| High school                      | 48 (25.3)  |
| University graduate              | 35 (18.4)  |
| Marital status                   |       |           |
| Single                           | 16 (8.4)   |
| Married                          | 160 (84.2) |
| Widow                            | 14 (7.4)   |

Table 2. Prevalence of depression, anxiety, and stress among breast cancer patients

| Variables | N (%) | Mean ± SD | Range |
|-----------|-------|-----------|-------|
| Depression|       |           |       |
| Normal    | 136 (71.6) | 6.7 ± 4.9 | 0–21  |
| Low       | 35 (18.4)  |           |       |
| Moderate  | 18 (9.5)   |           |       |
| Severe    | 1 (0.5)    |           |       |
| Anxiety   |       | 6.7 ± 4.3 | 0–18  |
| Normal    | 108 (56.8) |           |       |
| Low       | 26 (13.7)  |           |       |
| Moderate  | 50 (26.3)  |           |       |
| Severe    | 6 (3.2)    |           |       |
| Stress    |       | 8.9 ± 5.1 | 37–160|
| Normal    | 162 (85.3) |           |       |
| Low       | 24 (12.6)  |           |       |
| Moderate  | 3 (1.6)    |           |       |
| Severe    | 1 (0.5)    |           |       |
of the present study was the investigation of depression, anxiety, and stress concurrently. Another strength of the present study was that participants from different cities with different cultures were included, especially from areas where fewer studies had previously been carried out. The main limitations of the present study were as follows: 1. The sample size was low, which could limit the generalisation of results. 2. This is a descriptive study that should consider the specific limitations of these studies when interpreting the study results. 3. Variables were evaluated using self-report measures instead of non-clinical evaluation, which should thus be taken into consideration.

Conclusions

Results showed that approximately one-third of patients suffer from depression and about half of them from anxiety. The high prevalence of depression and anxiety indicates the importance of timely and periodic evaluation of psychological symptoms in patients with breast cancer.

Conflicts of interest

The authors declare to have no conflict of interest.

References

1. DeSantis CE, Ma J, Gaudet MM, et al. Breast cancer statistics, 2019. CA Cancer J Clin. 2019; 69(6): 438–451, doi: 10.3322/caac.21585, indexed in Pubmed: 31577379.
2. John R, Ross H. The global economic cost of cancer. Atlanta, GA: American Cancer Society and LIVESTRONG. 2010.
3. Cardoso F, Kyriakides S, Orno H, et al. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2019; 30(8): 1194–1220, doi: 10.1093/annonc/mdz173.
4. Chang L, Weiner LS, Hartmann SJ, et al. Breast cancer treatment and its effects on aging. J Geriatr Oncol. 2019; 10(2): 346–355, doi: 10.1016/j.jgo.2018.07.010, indexed in Pubmed: 30079714.
5. Charalampopoulos M, Kritseli E, Chrousos GP, et al. Efficacy of stress management and psychosocial interventions on body image in breast cancer survivors: A systematic review. Dialogues in Clinical Neuroscience & Mental Health. 2019; 2(4): 237–242.
6. Shm EJ, Lee JW, Cho J, et al. Association of depression and anxiety disorder with the risk of mortality in breast cancer: A National Health Service Insurance Study in Korea. Breast Cancer Res Treat. 2020; 179(2): 491–498, doi: 10.1007/s10549-019-05479-3, indexed in Pubmed: 31673880.
7. Kugbel N, Oppong Asante K, Meyer-Weitz A. Depression, anxiety and quality of life among women living with breast cancer in Ghana: mediating roles of social support and religiosity. Support Care Cancer. 2019 [Epub ahead of print], doi: 10.1007/s00520-019-05627-1, indexed in Pubmed: 31520120.
8. van Oers H. Aspects of Post-Traumatic Stress Disorder symptomsatology in patients with breast cancer: a review of prevalence, risk and mediating factors. World Scientific News. 2019; 120(2): 266–74.
9. Peng L, Huang W, Zhang W, et al. Psychometric properties of the short form of the fear of cancer recurrence inventory (FCRI) in chinese breast cancer survivors. Front Psychiatry. 2019; 10: 537, doi: 10.3389/fpsyg.2019.00537, indexed in Pubmed: 31447709.
10. Pilevarzadeh M, Aminshahi M, Afkarghareshbagh R, et al. Global prevalence of depression among breast cancer patients: a systematic review and meta-analysis. Breast Cancer Res Treat. 2019; 176(3): 519–533, doi: 10.1007/s10549-019-05271-3, indexed in Pubmed: 31087199.
11. Peoples AR, Garland SN, Pigeon WR, et al. Cognitive behavioral therapy for insomnia reduces depression in cancer survivors. J Clin Sleep Med. 2019; 15(1): 129–137, doi: 10.5666/jcsm.7566, indexed in Pubmed: 30621831.
12. Kim SC, Shaw BR, Shah DV, et al. Interactivity, presence, and targeted patient care: mapping e-Health intervention effects over time for cancer patients with depression. Health Commun. 2019; 34(2): 162–171, doi: 10.1080/10410236.2017.1399504, indexed in Pubmed: 29135321.
13. Hashemi SM, Rafieanrehashi A, Agharemmamadi T, et al. Prevalence of anxiety among breast cancer patients: a systematic review and meta-analysis. Breast Cancer. 2020; 27(2): 166–178, doi: 10.1007/s12822-019-01031-9, indexed in Pubmed: 31828585.
14. LeVasseur N, Li H, Cheung W, et al. Effects of high anxiety scores on surgical and overall treatment plan in patients with breast cancer treated with neoadjuvant therapy. Oncology. 2019 [Epub ahead of print]: 25(3): 212–217, doi: 10.1634/theoncologist.2019-0512, indexed in Pubmed: 31619949.
15. Tang Y, Fu F, Gao H, et al. Art therapy for anxiety, depression, and fatigue in females with breast cancer: A systematic review. J Psychosoc Oncol. 2019; 37(1): 79–95, doi: 10.1080/07347332.2018.1506855, indexed in Pubmed: 30422004.
16. An Y, Fu G, Yuan G. Quality of life in patients with breast cancer: the influence of family caregiver’s burden and the mediation of patient’s anxiety and depression. J Nev Ment Dis. 2019; 207(11): 921–926, doi: 10.1016/j.jnm.2019.04.010, indexed in Pubmed: 31517713.
17. Osman A, Wong JL, Bagge CL, et al. The Depression Anxiety Stress Scales-21 (DASS-21): further examination of dimensions, scale reliability, and correlates. J Clin Psychol. 2012; 68(12): 1322–1338, doi: 10.1002/jclp.21998, indexed in Pubmed: 22930477.
18. Aghaee A, Saeed F, Dilbajia J. Psychometric properties of the Depression Anxiety Stress Scales-21 (DASS-21) in a non-clinical Iranian sample. Int J Psychol. 2008; 2(2): 82–102.
19. Jafari P, Nozari F, Ahrafi F, et al. Measurement invariance of the Depression Anxiety Stress Scales-21 across medical student genders. Int J Med Educ. 2017; 8: 116–122, doi: 10.5116/ijme.58ba.7d8b, indexed in Pubmed: 28362630.
20. Oei TPS, Sawang S, Goh YW, et al. Using the Depression Anxiety Stress Scale 21 (DASS-21) across cultures. Int J Psychol. 2018; 48(6): 1018–1029, doi: 10.1002/ijp2.1170, indexed in Pubmed: 23425257.
21. Tonsing KN. Psychometric properties and validation of Nepali version of the Depression Anxiety Stress Scales (DASS-21). Asian J Psychiatr. 2014; 8: 63–68, doi: 10.1016/j.ajp.2013.11.001, indexed in Pubmed: 24655630.
22. von Elm E, Altman D, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Journal of Clinical Epidemiology. 2008; 61(4): 344–348, doi: 10.1016/j.jclinepi.2007.11.008.
23. Montazeri A, Sajadian A, Ebrahim M, et al. Depression and the use of complementary medicine among breast cancer patients. Support Care Cancer. 2005; 13(5): 339–342, doi: 10.1007/s00520-004-0709-z, indexed in Pubmed: 15549425.
24. Taghavi M, Kafali E, Talei A, et al. Investigating the relation of depression and religious coping and social support in women with breast cancer. Journal of Isfahan Medical School. 2011; 28(119).
25. Nikbakht N, Mouidi S, Abbasian S, et al. Prevalence of depression and anxiety among cancer patients. Caspian J Intern Med. 2014; 5(3): 167–170, indexed in Pubmed: 25202445.
26. Ramezani T. Degree of depression and the need for counseling among women with breast cancer in Kerman chemotherapeutic centers. 2001.
27. Mashhadi MA, Shakiba M, Zakeri Z. Evaluation of depression in patients with depression, anxiety, and stress concurrently. Int J Psychol. 2017; 8: 116–122, doi: 10.5116/ijme.58ba.7d8b, indexed in Pubmed: 24655630.
32. Lee Y, Chien C-Y, Fang F-M, Lin P-Y. Prevalence and risk factors of depression in patients with head and neck cancer: a literature review. International Journal of Head and Neck Science. 2019; 3(3): 140–51.

33. Peng YN, Huang ML, Kao CH. Prevalence of Depression and Anxiety in Colorectal Cancer Patients: A Literature Review. Int J Environ Res Public Health. 2019; 16(3), doi: 10.3390/ijerph16030411, indexed in Pubmed: 31444517.

34. Mahdavi A, Mosavimoghadam S, Madani Y, et al. Effect of intensive short-term dynamic psychotherapy on emotional expressiveness and defense mechanisms of women with breast cancer. Archives of Breast Cancer. 2019; 35–41, doi: 10.32768/abc.20196135-41.

35. Pinquart M, Duberstein PR. Depression and cancer mortality: a meta-analysis. Psychological Medicine. 2010; 40(11): 1797–1810, doi: 10.1017/s0033291709992285.

36. Caruso R, Breitbart W. Mental health care in oncology. Contemporary perspective on the psychosocial burden of cancer and evidence-based interventions. Epidemiol Psychiatr Sci. 2020; 29: e86, doi: 10.1017/S2045796019000235.

37. Larkin DR. Routine depression screenings for advanced cancer patients: reducing disparities, identifying depression, and improving quality of life. J Hosp Palliat Nurs. 2020; 22(1): 12–16, doi: 10.1097/Njh.0000000000000616, indexed in Pubmed: 31851036.

38. Grotnol K, Lie H, Loge J, et al. Patients with advanced cancer and depression report a significantly higher symptom burden than non-depressed patients. Palliative and Supportive Care. 2018; 17(2): 143–149, doi: 10.1017/s1478951517001183.

39. Serfaty M, King M, Nazareth I, et al. Effectiveness of cognitive-behavioral therapy for depression in advanced cancer: CanTalk randomised controlled trial. The British Journal of Psychiatry. 2019; 216(4): 213–221, doi: 10.1192/bjp.2019.207.

40. Lethborg C, Kissane DW, Schofield P. Meaning and Purpose (MaP) therapy I: Therapeutic processes and themes in advanced cancer. Palliat Support Care. 2019; 17(1): 13–20, doi: 10.1017/S1478951518000871, indexed in Pubmed: 30600795.

41. Lueboonthavatchai P. Prevalence and psychosocial factors of anxiety and depression in breast cancer patients. J Med Assoc Thai. 2007; 90(10): 2164–2174, indexed in Pubmed: 18041438.

42. Parada H, Sun X, Teo CK, et al. Lifestyle Patterns and Survival Following Breast Cancer in the Carolina Breast Cancer Study. Epidemiology. 2019; 30(1): 83–92, doi: 10.1097/EDE.0000000000000933, indexed in Pubmed: 30299494.

43. Bahri N, Farsi Najafi T, Hornaei Shandiz F, et al. The relation between stressful life events and breast cancer: a systematic review and meta-analysis of cohort studies. Breast Cancer Res Treat. 2019; 176(1): 53–61, doi: 10.1007/s10549-019-05231-x, indexed in Pubmed: 31004298.